• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

谷氨酰胺耗竭通过激活 EGFR/ERK/c-Jun 信号通路诱导肾癌中 PD-L1 的表达。

Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.

机构信息

Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Key Laboratory, Department of Urology and Andrology, The Affiliated Hospital of Qingdao University, Qingdao, China.

出版信息

Mol Cancer Res. 2020 Feb;18(2):324-339. doi: 10.1158/1541-7786.MCR-19-0517. Epub 2019 Oct 31.

DOI:10.1158/1541-7786.MCR-19-0517
PMID:31672701
Abstract

The programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) pathway plays a pivotal role in the immune escape of tumors. Many tumor cells show "glutamine dependence." However, the relationship between glutamine metabolism and PD-L1 expression has not been reported. In this study, changes in PD-L1 expression in renal carcinoma cells were evaluated during glutamine deprivation and recovery. Although PD-L1 expression differed in two renal cancer cell lines, both cell lines upregulated PD-L1 during glutamine deprivation, and the upregulated PD-L1 was restored to normal after glutamine recovery. Mechanistically, glutamine deprivation resulted in activation of EGFR signaling via ERKs 1 and 2 (ERK1/2) and c-Jun. In addition, treatment of renal cancer cells with EGF also induced PD-L1 expression and ERK1/2 phosphorylation. Finally, inhibitors of EGFR, ERK, and c-Jun all inhibited phosphorylation of c-Jun and downregulated PD-L1 expression induced by glutamine deprivation. Taken together, the data suggest that glutamine regulates the expression of PD-L1 through the EGFR/ERK/c-Jun pathway in renal cancer. IMPLICATIONS: This study reveals glutamine deprivation induces PD-L1 expression via activation of EGFR/ERK/c-Jun signaling in renal cancer and provides novel markers for the treatment of renal cancer.

摘要

程序性死亡配体 1/程序性死亡受体 1(PD-L1/PD-1)通路在肿瘤的免疫逃逸中发挥着关键作用。许多肿瘤细胞表现出“谷氨酰胺依赖性”。然而,谷氨酰胺代谢与 PD-L1 表达之间的关系尚未被报道。在本研究中,评估了肾癌细胞在谷氨酰胺剥夺和恢复过程中 PD-L1 表达的变化。虽然两种肾癌细胞系中 PD-L1 的表达存在差异,但这两种细胞系在谷氨酰胺剥夺时均上调 PD-L1,谷氨酰胺恢复后上调的 PD-L1 恢复正常。从机制上讲,谷氨酰胺剥夺通过 ERK1/2(ERK1/2)和 c-Jun 激活 EGFR 信号。此外,用 EGF 处理肾癌细胞也诱导 PD-L1 表达和 ERK1/2 磷酸化。最后,EGFR、ERK 和 c-Jun 的抑制剂均抑制 c-Jun 的磷酸化并下调谷氨酰胺剥夺诱导的 PD-L1 表达。总之,数据表明谷氨酰胺通过 EGFR/ERK/c-Jun 通路调节肾癌细胞中 PD-L1 的表达。意义:本研究揭示了谷氨酰胺剥夺通过激活肾癌细胞中的 EGFR/ERK/c-Jun 信号诱导 PD-L1 表达,并为肾细胞癌的治疗提供了新的标志物。

相似文献

1
Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.谷氨酰胺耗竭通过激活 EGFR/ERK/c-Jun 信号通路诱导肾癌中 PD-L1 的表达。
Mol Cancer Res. 2020 Feb;18(2):324-339. doi: 10.1158/1541-7786.MCR-19-0517. Epub 2019 Oct 31.
2
Immunosuppression Induced by Glutamine Deprivation Occurs Activating PD-L1 Transcription in Bladder Cancer.谷氨酰胺剥夺诱导的免疫抑制通过激活膀胱癌中PD-L1转录而发生。
Front Mol Biosci. 2021 Nov 5;8:687305. doi: 10.3389/fmolb.2021.687305. eCollection 2021.
3
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.经典的 TGF-β/Smad 信号通路参与了 EGFR 突变型非小细胞肺癌中 PD-L1 诱导的 EGFR-TKIs 原发性耐药。
Respir Res. 2019 Jul 22;20(1):164. doi: 10.1186/s12931-019-1137-4.
4
EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells.EFEMP2 通过 EGFR/ERK1/2/c-Jun 信号上调 PD-L1 表达,促进卵巢癌细胞侵袭。
Cell Mol Biol Lett. 2023 Jul 7;28(1):53. doi: 10.1186/s11658-023-00471-8.
5
EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.EGFR-ERK 通路调节 CSN6 促进胶质母细胞瘤中 PD-L1 的表达。
Mol Carcinog. 2020 May;59(5):520-532. doi: 10.1002/mc.23176. Epub 2020 Mar 5.
6
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.EGFR 激活介导 PD-L1 上调导致 EGFR 驱动 NSCLC 的免疫逃逸:对 EGFR 突变 NSCLC 患者进行可选免疫靶向治疗的意义。
J Thorac Oncol. 2015 Jun;10(6):910-23. doi: 10.1097/JTO.0000000000000500.
7
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.持续靶向激酶抑制剂治疗诱导耐药 NSCLC 中 PD-L1 的上调。
Sci Rep. 2019 Mar 6;9(1):3705. doi: 10.1038/s41598-018-38068-3.
8
Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.表皮生长因子诱导 STAT1 表达,加剧表皮生长因子受体阳性癌症中 IFNr 介导的 PD-L1 轴。
Mol Carcinog. 2018 Nov;57(11):1588-1598. doi: 10.1002/mc.22881. Epub 2018 Aug 28.
9
Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.Nagilactone E 通过激活肺癌细胞中的 c-Jun 增加 PD-L1 的表达。
Chin J Nat Med. 2020 Jul;18(7):517-525. doi: 10.1016/S1875-5364(20)30062-5.
10
An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.PD-L1诱导的BAG-1增加通过持续激活ERK信号通路赋予非小细胞肺癌对酪氨酸激酶抑制剂的抗性。
Eur J Cancer. 2017 Nov;85:95-105. doi: 10.1016/j.ejca.2017.07.025. Epub 2017 Sep 9.

引用本文的文献

1
Amino acids shape the metabolic and immunologic landscape in the tumor immune microenvironment: from molecular mechanisms to therapeutic strategies.氨基酸塑造肿瘤免疫微环境中的代谢和免疫格局:从分子机制到治疗策略。
Cancer Biol Med. 2025 Jul 24;22(7):726-46. doi: 10.20892/j.issn.2095-3941.2025.0115.
2
Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma.代谢相关的醛脱氢酶1B1(ALDH1B1)作为原发性胃肠道弥漫性大B细胞淋巴瘤的潜在预测指标和治疗靶点。
Apoptosis. 2025 Apr 11. doi: 10.1007/s10495-025-02112-1.
3
Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy.
靶向代谢脆弱性以对抗癌症治疗中的耐药性。
J Pers Med. 2025 Jan 27;15(2):50. doi: 10.3390/jpm15020050.
4
Metabolism and spatial transcription resolved heterogeneity of glutamine metabolism in cervical carcinoma.代谢与空间转录解析宫颈癌中谷氨酰胺代谢的异质性
BMC Cancer. 2024 Dec 6;24(1):1504. doi: 10.1186/s12885-024-13275-6.
5
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders.程序性死亡受体配体1:从癌症免疫疗法到在多种疾病中的治疗意义
Mol Ther. 2024 Dec 4;32(12):4235-4255. doi: 10.1016/j.ymthe.2024.09.026. Epub 2024 Sep 28.
6
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy.程序性死亡受体 (PD-)1/PD-配体 (L)1 在泌尿系统癌症中的作用:免疫治疗中的“全能战士”。
Mol Cancer. 2024 Sep 2;23(1):183. doi: 10.1186/s12943-024-02095-8.
7
Targeting amino acid-metabolizing enzymes for cancer immunotherapy.针对氨基酸代谢酶的癌症免疫疗法。
Front Immunol. 2024 Aug 14;15:1440269. doi: 10.3389/fimmu.2024.1440269. eCollection 2024.
8
Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma.解析透明细胞肾细胞癌中恶性肿瘤和肿瘤微环境的谷氨酰胺代谢模式。
Clin Exp Med. 2024 Jul 6;24(1):152. doi: 10.1007/s10238-024-01390-4.
9
Abnormal HCK/glutamine/autophagy axis promotes endometriosis development by impairing macrophage phagocytosis.异常的 HCK/谷氨酰胺/自噬轴通过损害巨噬细胞的吞噬作用促进子宫内膜异位症的发展。
Cell Prolif. 2024 Nov;57(11):e13702. doi: 10.1111/cpr.13702. Epub 2024 Jul 2.
10
complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of .与 IGF2BP3 复合可通过调节. 的 N6-甲基腺苷修饰来驱动葡萄膜黑色素瘤的进展。
Oncol Res. 2024 Apr 23;32(5):983-998. doi: 10.32604/or.2024.045972. eCollection 2024.